NCT06550531 Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
| NCT ID | NCT06550531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Human Papilloma Virus |
| Study Type | OBSERVATIONAL |
| Enrollment | 618 participants |
| Start Date | 2022-02-04 |
| Primary Completion | 2026-02-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 618 participants in total. It began in 2022-02-04 with a primary completion date of 2026-02-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.
Eligibility Criteria
Inclusion Criteria: * all etiology of infertility AMH \> ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months Exclusion Criteria: Age \< 25 y Age \> ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06550531 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 38 Years, studying Human Papilloma Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06550531 currently recruiting?
Yes, NCT06550531 is actively recruiting participants. Contact the research team at sarah.bouee@chu-brest.fr for enrollment information.
Where is the NCT06550531 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT06550531 clinical trial?
NCT06550531 is sponsored by University Hospital, Brest. The trial plans to enroll 618 participants.